VivoSeq
Neurology

Neuromyelitis Optica Spectrum Disorder

2

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Neuromyelitis Optica Spectrum Disorder is an early-stage landscape with 2 programs across 3 companies. The most active players are Roche, AstraZeneca, MedRhythms, Inc.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 3AstraZeneca logo

AstraZeneca

1 program

PreclinicalM

MedRhythms, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Ravulizumab

AstraZeneca

Phase 1
No programs
Phase 2
No programs
Phase 31

Satralizumab

Roche

Approved
No programs

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Enrolling by invitation1 · 33%
Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

A Phase III, Multicenter, Open-Label, Uncontrolled Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
Recruiting·Roche logoRoche·Phase 3·NCT05199688·8 enrolled
A Single Arm, Prospective, Multi-Center, Feasibility Study to Evaluate the Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder (NMOSD) Who Have an Impaired Gait
Enrolling by invitation·MMedRhythms, Inc.·Preclinical·NCT06374264·30 enrolled
A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 Antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)
Active, not recruiting·AstraZeneca logoAstraZeneca·Preclinical·NCT05346354·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)